Read More Pharma Industry News Are oral GLP-1 pills finally closing the credibility gap with injectables after ribupatide data Are oral GLP-1 and GIP agonists becoming viable after ribupatide’s Phase 2 data? Explore what this shift means for obesity drug strategy. bySoujanya RaviFebruary 14, 2026